Latest Conference Articles

CPHI Milan Brings Back Leadership Summit as Supply Chain and Manufacturing Pressures Ramp Up

September 21st 2026

The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.

CPHI Milan 2026: Trends in Pharma

September 17th 2026

PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.

CPHI Milan 2026: AI and Bioavailability, Part 2

September 17th 2026

Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.

Two Audit Case Studies Reveal the Cost of Incomplete Corrective Actions

September 16th 2026

PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.

Raw Material Complexities and Strategies with for Advanced Therapies

September 16th 2026

Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.

Lessons For AI Governance in Quality Systems

September 15th 2026

Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.

Successful Internal Audit Planning and Execution

September 15th 2026

At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.

Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response

September 15th 2026

At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.

CPHI Milan 2026: AI and Bioavailability, Part 1

September 14th 2026

Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains that developing a molecule requires a holistic view of its chemical, physical, and biological properties.

Shilpa CDMO to Launch as Dedicated Complex Small-Molecule Contract Development and Manufacturing Brand at CPHI Milan

September 10th 2026

Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.